193013-48-8 Usage
Chemical structure
A bicyclic organic compound with a benzimidazole ring, a methanol group at the 6th position, and a 2-methyl-1-[(2-chlorophenyl)methyl] group at the 1st position.
Molecular weight
Approximately 257.74 g/mol
Functional groups
Benzimidazole ring, methanol group, chlorophenyl group, and a methyl group.
Derivative
A derivative of benzimidazole, which is a bicyclic organic compound with nitrogen atoms at each of the two fused rings.
Pharmacological activities
Benzimidazole derivatives have been studied for their diverse pharmacological activities, including antiviral, antibacterial, antifungal, and anticancer properties.
Potential applications
As a potential drug candidate for various medical conditions due to its diverse pharmacological activities.
Chemical and biological properties
The addition of the 2-methyl-1-[(2-chlorophenyl)methyl] group to the benzimidazole ring increases the compound's complexity and introduces a chlorophenyl group, potentially altering its chemical and biological properties.
Solubility
The solubility of 1H-Benzimidazole-6-methanol, 1-[(2-chlorophenyl)methyl]-2-methyl- in various solvents is not explicitly mentioned in the provided material, but it can be inferred that it may have varying solubility depending on the solvent's polarity and hydrogen bonding ability.
Stability
The stability of 1H-Benzimidazole-6-methanol, 1-[(2-chlorophenyl)methyl]-2-methylis not explicitly mentioned in the provided material, but it can be inferred that the compound may be sensitive to certain conditions such as heat, light, or moisture, which could affect its stability and reactivity.
Synthesis
The synthesis of 1H-Benzimidazole-6-methanol, 1-[(2-chlorophenyl)methyl]-2-methyl- is not described in the provided material, but it can be inferred that it may involve the formation of the benzimidazole ring and subsequent functionalization with the methanol and 2-methyl-1-[(2-chlorophenyl)methyl] groups.
Purity
The purity of the compound is not mentioned in the provided material, but it is essential to consider when evaluating its pharmacological activities and potential applications.
Safety and handling
The safety and handling precautions for 1H-Benzimidazole-6-methanol, 1-[(2-chlorophenyl)methyl]-2-methyl- are not explicitly mentioned in the provided material, but it is crucial to follow standard laboratory safety protocols when working with potentially hazardous chemicals.
Check Digit Verification of cas no
The CAS Registry Mumber 193013-48-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,9,3,0,1 and 3 respectively; the second part has 2 digits, 4 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 193013-48:
(8*1)+(7*9)+(6*3)+(5*0)+(4*1)+(3*3)+(2*4)+(1*8)=118
118 % 10 = 8
So 193013-48-8 is a valid CAS Registry Number.
193013-48-8Relevant academic research and scientific papers
Benzimidazole compounds
-
Page column 83, (2010/02/05)
A benzimidazole compound represented by the formula (I): wherein R3is a carboxyl group, a esterified carboxyl group, an amidated carboxyl group, an amino group, an amido group, or a sulfonyl group, or their pharmaceutically acceptable salts. Because of their blood sugar-depressing effect or PDE5 inhibitory effect, these compounds or salts thereof are useful as medicines for treating impaired glucose tolerance, diabetes, diabetic complications, syndrome of insulin resistance, hyperlipidemia, atherosclerosis, cardiovascular disorders, hyperglycemia, or hypertension; or stenocardia, hypertension, pulmonary hypertension, congestive heart failure, glomerulopathy, tubulointerstitial disorders, renal failure, atherosclerosis, angiostenosis, distal angiopathy, cerebral apoplexy, chronic reversible obstructions, allergic rhinitis, urticaria, glaucoma, diseases characterized by enteromotility disorders, impotence, diabetic complications, nephritis, cancerous cachexia, or restenosis after PTCA.
Benzimidazole derivatives
-
, (2008/06/13)
PCT No. PCT/JP96/03858 Sec. 371 Date Nov. 2, 1998 Sec. 102(e) Date Nov. 2, 1998 PCT Filed Dec. 27, 1996 PCT Pub. No. WO97/24334 PCT Pub. Date Jul. 10, 1997Novel benzimidazole derivatives represented by the formula (I): wherein R3 is a carboxyl group, a esterified carboxyl group, an amidated carboxyl group, an amino group, an amido group, or a sulfonyl group, or their pharmaceutically acceptable salts. Because of their blood sugar-depressing effect or PDE5 inhibitory effect, these compounds or salts thereof are useful as medicines for treating impaired glucose tolerance, diabetes, diabetic complications, syndrome of insulin resistance, hyperlipidemia, atherosclerosis, cardiovascular disorders, hyperglycemia, or hypertension; or stenocardia, hypertension, pulmonary hypertension, congestive heart failure, glomerulopathy, tubulointerstitial disorders, renal failure, atherosclerosis, angiostenosis, distal angiopathy, cerebral apoplexy, chronic reversible obstructions, allergic rhinitis, urticaria, glaucoma, diseases characterized by enteromotility disorders, impotence, diabetic complications, nephritis, cancerous cachexia, or restenosis after PTCA.
